Assessing the high potential of the Russian pharmaceutical market, GEN started its first operational activity in Russia in 2014. In March 2020, the Russian Representative Office of GEN was opened to expand its portfolio and actively promote original and highly demanded competitive drugs. In 2017, the Ministry of Industry and Trade of the Russian Federation inspected the manufacturing site of GEN and awarded a certificate of compliance with the GMP standard.